Franz Hefti, co-director of the Lilly Institute for Genetic Medicine and CEO of Lilly sub Prevail

Lil­ly breaks the bank on the po­ten­tial for RNA with $700M in­vest­ment in Boston's Sea­port

In the lat­est boom across drug R&D, Big Phar­ma has dumped bil­lions in­to re­search for RNA-based ther­a­pies, bet­ting big on the fu­ture in that space …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.